# Maison Capital

> Maison Capital is a VC fund backing Health Care and Artificial Intelligence. See 38 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Grand Cayman, Cayman Islands
- Total investments: 38
- Last investment: Apr 2022
- Lead investor: 34%
- Fund size: $200M
- Last fund: Jun 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/maison-capital
- Website: http://www.maisoncapital.com

Maison Capital is a private equity firm that invests in the consumer growth sectors.

## Contacts

5 contacts available for Maison Capital. Shizune tracks 1 team members at Maison Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/maison-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.4M–$20M |
| Series B | $2.8M–$122M |
| Series C | $4.3M–$255M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 21% |
| Artificial Intelligence | 6 | 16% |
| Biotechnology | 5 | 13% |
| Medical | 4 | 11% |
| Electronics | 4 | 11% |

55 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 29% |
| Series B | 10 | 26% |
| Series C | 5 | 13% |
| Angel | 4 | 11% |
| Seed | 2 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 30 | 79% |
| France | 1 | 3% |
| Hong Kong | 1 | 3% |
| United States | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Wenli Cui | Founder & Managing Partner | 0 | https://shizune.co/investors/profile/wenli-cui-2308 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enxi Village | Enxi Village is a frozen bakery brand and a leading domestic frozen bakery large-scale and automated production enterprise. |  | Series B | Apr 21, 2022 |  |
| AUTHINE | AUTHINE is a digital platform service provider company. | $15.8M | Series C | Mar 01, 2022 |  |
| AUTHINE | AUTHINE is a digital platform service provider company. | $15.8M | Series C | Mar 01, 2022 |  |
| YUSUR Technology | YUSUR Technology is a Chinese startup on data processing units |  | Series A | Dec 21, 2021 |  |
| YUSUR Technology | Zhongke Digital is a Chinese company that specializes in the development of dedicated computing architectures for finance, artificial intelligence, and blockchain. The company is based in Beijing. China. |  | Series A | Dec 21, 2021 |  |
| Zbeetle | Zbeetle is a cleaning robot developer. Its subsidiary provides users with products and services such as intelligent robots based on the application of robot technology to help users solve the problem of indoor environmental cleanliness. | $15.7M | Seed | Nov 19, 2021 |  |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $255M | Series C | Jun 22, 2021 |  |
| HiFiBiO Therapeutics | HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $75M | Series D | Jun 14, 2021 |  |
| Yongpu Kafei | Yongpu Kafei is a coffee brand. | $7.8M | Series A | Jun 10, 2021 |  |
| Elpiscience Biopharmaceuticals | Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpscience’s first therapeutic product ES101 has entered into clinical trial, and the secondinnovative product ES102 is IND ready. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by top investors such as Lilly Asia Ventures, Hillhouse Capital and CDH Investment. | $105M | Series C | May 13, 2021 |  |

10 of 38 investments shown.

## Co-investors
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 4 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 3 deals together
- [Oriental Fortune Capital](https://shizune.co/investors/profile/oriental-fortune-capital) — VC Fund, 3 deals together
- [Oriza Holdings](https://shizune.co/investors/profile/oriza-holdings) — VC Fund, 3 deals together
- [Jade Capital](https://shizune.co/investors/profile/ancient-jade-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Warner Music Group](https://shizune.co/investors/profile/warner-music-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Goodwater Capital](https://shizune.co/investors/profile/goodwater-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Music VC Funds in Asia](https://shizune.co/investors/music-vc-funds-asia)
- [Music Investors in China](https://shizune.co/investors/music-investors-china)
- [Music VC Funds in China](https://shizune.co/investors/music-vc-funds-china)

## FAQ

### What does Maison Capital invest in?

Maison Capital invests primarily in Health Care, Artificial Intelligence and Biotechnology startups, most often at Series A and Series B stage. Most of the 38 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Maison Capital's check size?

Maison Capital typically joins rounds of $1.4M–$20M at Series A, $2.8M–$122M at Series B and $4.3M–$255M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Maison Capital participates in.

### How do I contact Maison Capital?

Public channels for Maison Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Maison Capital?

The team at Maison Capital includes Wenli Cui (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co